Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year
Tweet Send to a Friend
In a note late Wednesday, Wedbush substantially raised its price target Outperform-rated Sarepta Therapeutic (NASDAQ: SRPT) from $26 to $70 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
